Fit-assessed, protocol by protocol.
Not another firmographic search tool.

A CRO's leadership declares oncology, pediatrics, and rare disease as strategic focus, but the rep actually winning deals built her whole pipeline around a therapeutic area no one had flagged as a priority.

A BD team spends years pursuing a single sponsor account that was never going to convert, and nothing surfaces that until it's far too late.

Prospects get bucketed by broad therapeutic area alone, and teams end up responding to RFPs that amount to free consulting with no real shot at winning.

Bid timelines slip, and reps spend as much energy apologizing for the delay as they do making the actual case.

A CRO's most differentiated, winnable edge, a leadership team's real track record in a specific indication, rarely makes it into the pitch at all, buried under generic capability language.

Without a way to score fit before committing, teams default to bidding on nearly everything that crosses the desk, instead of prioritizing the strongest matches.

Screening quality depends on tribal knowledge passed down through training, not something a new rep can rely on consistently as the team grows.